De novo design of a novel oxazolidinone analogue as a potent and selective alpha1A adrenergic receptor antagonist with high oral bioavailability.
Lagu
B
B
Department of Chemistry, Synaptic Pharmaceutical Corporation, Paramus, New Jersey 07652, USA. blagu@prius.jnj.com
Tian
D
D
Jeon
Y
Y
Li
C
C
Wetzel
J M
JM
Nagarathnam
D
D
Shen
Q
Q
Forray
C
C
Chang
R S
RS
Broten
T P
TP
Ransom
R W
RW
Chan
T B
TB
O'Malley
S S
SS
Schorn
T W
TW
Rodrigues
A D
AD
Kassahun
K
K
Pettibone
D J
DJ
Freidinger
R O
RO
Gluchowski
C
C
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000138:chemical synthesis* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000502:physiology; D001667:Binding, Competitive; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D010080:Oxazoles / Q000138:chemical synthesis* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D011312:Pressure; D011467:Prostate / Q000187:drug effects / Q000502:physiology; D011869:Radioligand Assay; D051381:Rats; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects*; D011994:Recombinant Proteins / Q000138:chemical synthesis / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D014521:Urethra / Q000187:drug effects / Q000502:physiology
C547713:ADRA1A protein, human; D000317:Adrenergic alpha-Antagonists; D010080:Oxazoles; D018340:Receptors, Adrenergic, alpha-1; D011994:Recombinant Proteins; C412726:SNAP 7915